Kobayashi Pharmaceuticals
Kobayashi Pharmaceuticals Co., Ltd., commonly known as Kobayashi, is a leading player in the pharmaceutical and consumer healthcare industry, headquartered in Japan. Established in 1907, the company has a rich history marked by innovation and growth, with significant operations across Asia and beyond. Kobayashi is renowned for its diverse range of products, including over-the-counter medications, personal care items, and health supplements. Their unique formulations and commitment to quality set them apart in a competitive market. With a strong focus on research and development, Kobayashi has achieved notable milestones, solidifying its position as a trusted name in healthcare. The company continues to excel, leveraging its expertise to meet the evolving needs of consumers, while maintaining a reputation for excellence in product efficacy and safety.
DitchCarbon Score
How does Kobayashi Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Kobayashi Pharmaceuticals's score of 39 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Kobayashi Pharmaceuticals's reported carbon emissions
In 2022, Kobayashi Pharmaceuticals reported total greenhouse gas emissions of approximately 577,000,000 kg CO2e, with significant contributions from Scope 1, Scope 2, and Scope 3 emissions. Specifically, Scope 1 emissions were about 6,000,000 kg CO2e, while Scope 2 emissions totalled approximately 18,000,000 kg CO2e (market-based) and 21,000,000 kg CO2e (location-based). The most substantial impact came from Scope 3 emissions, which reached about 551,000,000 kg CO2e, primarily driven by purchased goods and services at approximately 445,000,000 kg CO2e. Kobayashi Pharmaceuticals has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 51% by 2030, using 2018 as the base year. Additionally, the company targets a 15% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. Overall, Kobayashi Pharmaceuticals is actively working towards significant emissions reductions, reflecting its commitment to sustainability and climate action in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 6,635,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 23,036,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000,000 | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Kobayashi Pharmaceuticals is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
